Tesamorelin
Egrifta · GHRH analog
The Ground Truth Score
four plain questions, never one numberProven
Bottom line
The grown-up in the room: FDA-approved, studied in proper randomized trials, with a known and manageable risk profile, the standard every wellness peptide on this site is measured against.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
FDA-approvedPrescription medicineAn approved drug with a label, a manufacturer, and a prescribing route. This is the only tier where what is in the vial is guaranteed by anyone. Check the indication, though: approval is always for something specific, and it is rarely the use this compound is popular for.
Approved by FDA as Egrifta for HIV-associated lipodystrophy. Approved for that indication, which is narrower than the anti-aging and body-composition uses it is marketed for.
Legal status as of 2026-06-16. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Here we can cite an actual approved dose, not a rumor: 2 mg subcutaneously daily (original Egrifta), or 1.28 mg subcutaneously once daily (EGRIFTA WR, the room-temperature formulation.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Well-documented. Studied in registrational human trials leading to FDA approval in 2010 for HIV-associated lipodystrophy; the room-temperature formulation EGRIFTA WR was FDA-approved in March 2025.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Reduces visceral (deep abdominal) fat.
- Lowers liver fat and may improve fatty-liver disease.
- Raises growth hormone and IGF-1 relatively physiologically; reported to support sleep.
The data behind each bullet
What actually backs it
Reduces visceral fat.
Phase 3 randomized trials showed ~15% visceral-fat reduction over 26 weeks versus placebo, the basis for FDA approval.
Falutz et al., NEJM 2007 — pivotal Phase 3 (15.2% VAT/26 wk) ↗Lowers liver fat.
In an HIV-population RCT, 2 mg daily for 12 months cut hepatic fat fraction ~37% versus placebo, with less fibrosis progression. Non-HIV NAFLD trials are ongoing.
Stanley et al., Lancet HIV 2019 — liver fat −37%/12 mo ↗Improves cognition.
Worth flagging the negative result honestly: a January 2025 RCT did NOT show significant cognitive benefit over placebo, despite earlier promise. We grade what the trials actually found.
Ellis et al., J Infect Dis 2025 — negative cognition RCT ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
Serial DEXA showing visceral-fat (VAT) reduction over 3-6 months is the direct, trial-proven proof it's working.
Bloodwork
A lab moves, but it's noisy, indirect, or off-target — treat it as a hint, not proof.
Tesamorelin is a GHRH analog that stimulates pulsatile pituitary GH release, which drives hepatic IGF-1 production. IGF-1 is a routine serum test, so the drug's on-target pharmacodynamic action (GH-axis stimulation) shows up clearly in standard bloodwork. The catch: a rising IGF-1 confirms the drug is biologically active and that the axis was engaged, but it is an indirect proxy for the actual therapeutic endpoint (visceral/liver fat loss), which was measured by CT imaging in every pivotal trial, not by blood.
A clear rise above the patient's own baseline (in the pivotal HIV-lipodystrophy trial IGF-1 rose ~81% from baseline at 26 weeks), staying within the top of the age/sex-adjusted range. This confirms target engagement (the GH axis was stimulated), not the clinical outcome itself.
GHRH analog -> pulsatile pituitary GH release -> hepatic IGF-1. IGF-1 is the standard integrated readout of GH-axis stimulation and the FDA-label-mandated monitoring analyte for this drug, but it is monitored chiefly for safety and reflects target engagement rather than the therapeutic fat-loss endpoint.
Draw baseline
before first dose
Retest
IGF-1 at 4-8 weeks (a rise can appear within ~2 weeks)
Read this before you spend on labs
Graded partial, not direct: IGF-1 is a cheap, orderable, on-target proxy and is the exact analyte the FDA label tells prescribers to monitor, so a rise reliably shows the drug is pharmacologically active in this person. But (1) IGF-1 confirms target engagement / GH-axis stimulation, not the intended clinical outcome; the actual therapeutic effect (visceral and liver fat loss) requires imaging or waist measurement, not blood. (2) The FDA monitors IGF-1 mainly for safety (keep it from exceeding the range, linked to theoretical cancer/IGF-1 risk), so interpret against an age/sex-adjusted range, not a fixed cutoff. (3) Glucose and HbA1c can WORSEN on tesamorelin because GH is diabetogenic; that is a safety signal, not evidence the drug is 'working.' The fasting-triglyceride drop seen in trials was dropped from this audit as an efficacy marker because it is diet-confounded, noisy, and not attributable per-person.
- Falutz et al., Metabolic effects of a growth hormone-releasing factor in patients with HIV, NEJM 2007 (IGF-1 +81%) - PMID 18057338 ↗
- Stanley et al., Effect of tesamorelin on visceral fat and liver fat in HIV, JAMA 2014 - PMID 25038357 ↗
- FDA EGRIFTA SV (tesamorelin) Prescribing Information - 'Monitor IGF-1 levels during EGRIFTA SV therapy' ↗
Other ways to track it
DEXA with VAT software (Hologic CoreScan / GE Lunar iDXA) — visceral adipose tissue (VAT), plus total lean mass as a secondary readout
A working course shows a measurable drop in VAT (and often a modest rise in lean mass). The pivotal HIV-lipodystrophy Phase 3 trials averaged roughly a 15% placebo-subtracted VAT reduction over 26 weeks, measured by CT/MRI; DEXA-VAT is the consumer-accessible surrogate for that same abdominal depot (well-correlated with CT but not the exact modality the trials used, so treat it as a close proxy). VAT moves slowly, so expect little at 4-6 weeks and the real signal by 3-6 months.
Tesamorelin is a GHRH analogue whose FDA-approved, trial-proven endpoint IS visceral-fat reduction. VAT is the actual therapeutic target, unlike IGF-1, which only confirms the GH axis was engaged, not that fat came off.
MRI-PDFF / 1H-MRS (gold standard) or FibroScan with CAP (widely accessible) — hepatic fat fraction
Liver-fat percentage should fall on repeat imaging. In a dedicated HIV/NAFLD trial (Stanley et al., Lancet HIV 2019), 2 mg daily cut hepatic fat fraction by roughly a third over ~12 months on MR spectroscopy and slowed fibrosis progression. FibroScan CAP is the accessible but noisier surrogate; MRI-based imaging is the clean but costlier read. Changes are slow.
Reduced liver fat is a validated secondary effect of tesamorelin's GH-mediated lipolysis, studied specifically in a dedicated HIV/NAFLD imaging trial — a real, imageable efficacy signal, though secondary to VAT and needing specialized imaging.
Tape-measure waist circumference at the umbilicus (same landmark, morning, fasted)
Waist should trend down as VAT falls. It's a near-free at-home proxy but is confounded by subcutaneous fat, hydration, posture and meal timing, so treat a 1-2 cm wobble as noise and look for a sustained multi-week downtrend, not any single reading. Note: total scale weight typically stays roughly flat in trials because the drug redistributes fat rather than driving large net loss, so do NOT use body weight as an efficacy signal — track waist, not the scale.
Waist circumference correlates with visceral adiposity and was tracked alongside imaging in the trials; it's the honest stand-in when serial DEXA isn't available, not a substitute for it.
Bottom line
The clean, trial-proven readout is falling visceral fat on serial DEXA (VAT) over 3-6 months; blood IGF-1 only tells you the GH axis fired, not that fat is coming off. Liver-fat imaging captures a real secondary benefit, and a waist tape is the cheap home proxy (noisy, sub-Q-confounded) — but ignore scale weight, which stays roughly flat since the drug redistributes rather than sheds mass. One safety caution: tesamorelin is diabetogenic, so a CGM or fasting glucose will often drift UP — that's a safety signal, not evidence it's working, so do not read glucose/CGM as an efficacy tracker. Sleep, VO2max, urine, stool, and genetics have no validated human efficacy proxy here.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
Established, not assumed: tesamorelin is a GHRH analog, it tells the pituitary to release the body's own growth hormone in a relatively natural, pulsatile way, which reduces visceral fat. Proven in human trials.
Dosing & handling
What users and clinicians report
Here we can cite an actual approved dose, not a rumor: 2 mg subcutaneously daily (original Egrifta), or 1.28 mg subcutaneously once daily (EGRIFTA WR, the room-temperature formulation. 0.16 mL reconstituted). Some users run a lower evening dose for sleep and liver goals rather than the full visceral-fat dose. Prescription and physician monitoring are the norm, and the point.
Even with an approved compound, dose and monitoring belong with a prescriber. The numbers here are the label, not personal medical advice.
Timing & food
2 mg daily (or 1.28 mg daily for EGRIFTA WR), typically at night and on an empty stomach, because glucose and insulin blunt growth-hormone release, and the goal is to ride the body's natural nighttime GH pulse.
Half-life
Short, tesamorelin clears quickly, which is why it's dosed daily. The newer EGRIFTA WR formulation keeps the once-daily cadence but adds room-temperature stability and a smaller injection volume.
Reconstitution sensitivity
A pharmaceutical product with real manufacturer quality control, a major advantage over gray-market peptides. The original needs refrigeration and careful reconstitution; the room-temperature WR version is more forgiving (room-temp storage, lower injection volume).
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate, more than MOTS-c, less than BPC-157; deep off-label threads plus on-label patient reviews.
Consistency
Visceral-fat loss and IGF-1 rise converge and are self-policing, the community warns it hits visceral, not subcutaneous, fat.
Source credibility
Unusually checkable, a real FDA/clinical spine exists, but we keep the community-signal grade separate from that halo.
- Users and patients consistently report visceral and abdominal fat reduction, and here it is backed by trials, not just stories.
- Improved sleep and body composition are common reports.
- Injection-site reactions, joint aches, and fluid retention are the usual complaints, matching the trial data.
Placebo risk, Low
Its headline effect, visceral fat, is measured on a scan in controlled trials. This is the one where the result is real, not a feeling.
Risk panel
What could go wrong
Adverse events
Well-characterized from registration trials: injection-site reactions, joint pain, peripheral edema, muscle pain. These are documented frequencies, not guesses.
Theoretical concerns
Raises IGF-1, so cancer screening and monitoring are advised; can affect glucose metabolism. Don't stack with other GH-promoting peptides without physician oversight.
Contraindications
Active malignancy; pregnancy; disrupted pituitary axis. Monitor IGF-1, glucose and PSA.
Honest unknowns
Long-term outcomes in non-HIV populations are still being studied; the cognitive question is effectively answered as negative.
Confound watch
Because it's prescribed and monitored, tesamorelin is less confounded than the wellness peptides, but body-composition users still typically combine it with training, GLP-1s or TRT, so isolate the variable if you want to know what it's doing for you.
History
Discovery → first use → status
- 2010FDA approves tesamorelin (Egrifta) for HIV-associated lipodystrophy.
- 2010sRCTs extend the evidence to liver fat (NAFLD) in HIV populations.
- Jan 2025Cognition RCT reports no significant benefit, an honest negative.
- Mar 2025EGRIFTA WR, a room-temperature, reduced-volume formulation (1.28 mg SC once daily), FDA-approved (available Sept 2025).
Verification
The COA standard, applied
Pharmaceutical tesamorelin (Egrifta / EGRIFTA WR) is FDA-regulated and arrives with manufacturer quality assurance, a major advantage over gray-market compounds. If sourced from a compounding pharmacy instead, apply the full COA standard and confirm the pharmacy's licensure.
The full verification standard →Sources
Where this comes from
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.